Victor Sandor - 17 Jun 2022 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
Director
Signature
/s/ Laurent Chardonnet, Attorney-in-Fact
Issuer symbol
PRLD
Transactions as of
17 Jun 2022
Net transactions value
$0
Form type
4
Filing time
22 Jun 2022, 16:14:17 UTC
Previous filing
02 Jun 2022
Next filing
03 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Director Stock Option (Right to Buy) Award $0 +34,300 $0.000000 34,300 17 Jun 2022 Common Stock 34,300 $4.74 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.